



## ASX & Media Release

### Patrys Quarterly Activities Report and Appendix 4C

**Melbourne, Australia, 29 October 2019:** Patrys Limited (ASX:PAB, “Patrys” or the “Company”), a therapeutic antibody development company, is pleased to announce further progress across its Deoxymab platform and the release of its Appendix 4C for the quarter ended 30 September 2019.

#### Key highlights

- Released pre-clinical animal data highlighting that PAT-DX1 increased tumour suppression, improved survival and enhanced radiation therapy of aggressive glioblastoma
- Planning underway for further PAT-DX1 and PAT-DX1-NP pre-clinical studies
- Presented at the 15<sup>th</sup> Bioshares Biotech Summit held in Queenstown, New Zealand
- Patrys and the Yale School of Medicine presented key pre-clinical findings at the Society for Neuro-Oncology Inaugural Conference on Brain Metastases in New York, US
- Strong cash balance at the close of quarter of A\$5.4m and net cash outflows of A\$1.1m including A\$578k invested in R&D associated with the Company’s pre-clinical studies

#### Operations

In July 2019, Patrys released new pre-clinical animal data regarding its lead candidate, PAT-DX1. Results from the study showed that PAT-DX1 as a single agent suppressed tumour growth in a highly aggressive human glioblastoma (GBM) mouse model and improved survival with no toxicity observed. In addition, PAT-DX1 in combination with low dose radiation resulted in significantly more tumour suppression and prolonged survival, compared to low dose radiation alone. This study was conducted by the Yale School of Medicine and forms part of the Company’s broader program to identify and optimise dosing regimens for future studies.

The Company continued planning for further PAT-DX1 and PAT-DX1-NP animal studies in GBM and triple negative breast cancer (TNBC) brain metastases. Patrys will continue to strengthen and extend its pre-clinical data package with planning currently underway for further pharmacokinetics, safety and toxicology studies, to inform the Company’s clinical development strategy. Patrys remains on track to initiate a phase 1 clinical study of PAT-DX1 at the end of CY20.

Patrys received a “Notice of Grant” for European patent (patent number: 2694555) titled “Cell-penetrating anti-DNA antibodies and uses thereof to inhibit DNA repair” in July 2019. The patent covers the methods of using Patrys’ novel Deoxymab 3E10 technology, including the lead candidate (PAT-DX1), as treatment for a broad range of cancers and malignancies including gliomas, metastases, breast, pancreatic, ovarian and prostate cancers and melanomas. Patrys is focused on maintaining patent protection in major jurisdictions where future regulatory approvals and product sales are targeted, with more than 20 pending patent applications across 9 patent families.

During the quarter, further progress was made on the cell line development of PAT-DX1 by a well-respected international service provider. Development of a stable cell line remains on track for completion in 1H CY20.



## Corporate

During the quarter, Patrys had net cash outflows of A\$1.1m with A\$578k invested in R&D associated with the Company's pre-clinical studies. At the end of the quarter, the Company held A\$5.4m in cash. Forecast cash outflow for the upcoming quarter is A\$1.1m, demonstrating Patrys' continued prudent cash management, where a significant portion of cash outflow is related to R&D activities.

In July 2019, Dr. James Campbell, Chief Executive Officer and Managing Director, presented at the 15<sup>th</sup> Bioshares Biotech Summit held in Queenstown, New Zealand. The summit provided an opportunity to showcase pre-clinical data from the Deoxymab 3E10 platform to fund managers and retail investors.

In August 2019, Dr. James Campbell and Dr. James Hansen, from the Yale School of Medicine, presented at the Society for Neuro-Oncology inaugural conference on Brain Metastases in New York, US. The presentation highlighted key data from the Company's pre-clinical development program, including findings that PAT-DX1 crosses the blood brain barrier, suppresses brain tumour growth and increases survival in animal studies of TNBC brain metastases. In addition, the conference provided an opportunity to present Patrys' nanoparticle conjugation approach (PAT-DX1-NP) and its potential to enable targeted delivery of therapeutics and improve patient outcomes.

**-Ends-**

To learn more please visit: [www.patrys.com](http://www.patrys.com)

### For further information, please contact:

#### General enquiries

James Campbell  
Chief Executive Officer  
P: +61 3 9670 3273  
[info@patrys.com](mailto:info@patrys.com)

#### Media enquiries:

Kyahn Williamson  
Buchan Consulting  
P: +61 3 9866 4722  
[kwilliamson@we-buchan.com](mailto:kwilliamson@we-buchan.com)

### About Patrys Limited

Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com).



**About Patrys' Deoxymab 3E10 platform – lead candidates PAT-DX1 and PAT-DX1-NP:**

Deoxymab 3E10 is a DNA damage-repair antibody that was first identified in lupus. Of particular interest is that whilst most antibodies bind to cell surface markers, Deoxymab 3E10 penetrates into the cell nuclei and binds directly to DNA where it inhibits DNA repair processes and kills cells that have mutations or deficiencies in DNA repair mechanisms as found in various cancer cells. Deoxymab 3E10 has demonstrated single agent activity and has been shown to significantly enhance the efficacy of both chemotherapy and radiotherapy. Further, Deoxymab 3E10 can be conjugated to nanoparticles to target delivery of chemotherapeutics and imaging agents to tumours.

Patrys has developed a humanised form of Deoxymab 3E10, PAT-DX1 with improved activity over the original version of 3E10, and is progressing this, and a nanoparticle-conjugated form (PAT-DX1-NP) towards the clinic. In a range of pre-clinical cancer models PAT-DX1 has shown significant ability to kill cancer cells in cell models, human tumour explants, xenograft and orthotopic models. Treatment with PAT-DX1 has been shown to significantly improve survival in orthotopic models of both triple negative breast cancer brain metastases and glioblastoma. Significantly, PAT-DX1 has repeatedly been shown to be able to cross the blood brain barrier, a significant hurdle for therapeutics to combat brain cancers.

Patrys' rights to Deoxymab 3E10 are part of a worldwide license to develop and commercialise as anti-cancer and diagnostic agents a portfolio of novel anti-DNA antibodies and antibody fragments, variants and conjugates discovered at Yale University.

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

Patrys Limited

**ABN**

97 123 055 363

**Quarter ended ("current quarter")**

30 September 2019

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (3 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	-	
1.2 Payments for		
(a) research and development	(578)	(578)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(214)	(214)
(f) administration and corporate costs	(244)	(244)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	26	26
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	
1.8 Other		
- IP expenditure	(61)	(61)
- Insurance Settlement	-	
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(1,071)</b>	<b>(1,071)</b>

<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (cash on deposits)	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>-</b>	<b>-</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
<b>3.10 Net cash from / (used in) financing activities</b>	<b>-</b>	<b>-</b>

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	6,474	6,474
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(1,071)	(1,071)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4 Net cash from / (used in) financing activities (item 3.10 above)	-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (3 months) \$A'000</b>
4.5	Effect of movement in exchange rates on cash held	(3)	(3)
<b>4.6</b>	<b>Cash and cash equivalents at end of quarter</b>	<b>5,400</b>	<b>5,400</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	1,292	2,390
5.2	Call deposits	4,108	4,084
5.3	Bank overdrafts	-	-
5.4	Other	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>5,400</b>	<b>6,474</b>

**6. Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

<b>Current quarter \$A'000</b>
195
-

Cash payments to directors for executive director salaries, non-executive director fees and consulting services for the quarter.

**7. Payments to related entities of the entity and their associates**

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

<b>Current quarter \$A'000</b>
-
-

-

8. <b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

-

9. <b>Estimated cash outflows for next quarter</b>	\$A'000
9.1 Research and development	667
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	-
9.5 Staff costs	109
9.6 Administration and corporate costs	146
9.7 Other (provide details if material) (IP)	188
<b>9.8 Total estimated cash outflows</b>	<b>1,110</b>

10. <b>Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	Acquisitions	Disposals
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets	-	-
10.5 Nature of business	-	-

**Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here: .....  
(Company secretary)

Date: 29 October 2019

Print name: Melanie Leydin

**Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.